NL-OMON37502已完成不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients - Phosphoproteomics for prediction of response to treatment in kidney cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients with advanced (unresectable and/or metastatic) renal cell cancer;
- •Patients who will start treatment with sunitinib, pazopanib, sorafenib, axitinib or everolimus;
- •At least one tumor lesion should be accessible for biopsy. Bone metastases are excluded as possible biopsy site;
- •Age >- 18 years;
- •Patients must have at least one measurable lesion. Lesions must be evaluated by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST);
- •WHO performance status 0 - 2;
- •Able to provide written informed consent;
排除标准
- •Clinical findings associated with an unacceptably high tumor biopsy risk, according to the judgement of the investigator;
- •Radiotherapy on target lesions during study or within 4 weeks of the start of study drug;
- •Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study;
研究者
相似试验
进行中（未招募）
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientsEUCTR2011-006009-85-NLVU University medical center225
招募中
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients.Phosphoproteomics - phosphoproteomicsResponse prediction - therapieselectierenal cell cancer - nierkankerkinase inhibitors - kinaseremmersNL-OMON26770VU Medical Center225
尚未招募
Unknown
A Clinical Study on Drug Resistance in CML(Chronic Myeloid Leukemia)CTRI/2024/08/072505Indian Council Of Medical Research
终止
不适用
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer PatientsRenal Cell CancerNCT02071719M. Labots6
进行中（未招募）
不适用
Factors affecting tyrosine kinase inhibitors response in chronic myeloid leukemia patientsDespite the excellent efficacy obtained for the treatment of CML,a significant proportion of patients develop resistance to tyrosine kinase inhibitors.TCTR20180703001/A100